U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07761572) titled 'CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension' on Aug. 06.
Brief Summary: This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or switch study treatment for Treatment Period 2 through Week 52.
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
Pulmonary Arterial Hypertension
Intervention:
DRUG: CS1
160 mg delayed release capsules taken orally once daily in the even...